Activities of the principal brain vesicular monamine transporter, VMAT2, are key to understanding the cellular compartmentalization of monoamines. They may play key roles in modulating the actions and neurotoxicities induced by amphetamine and by each of the toxins that selectively kills dopaminergic neurons to provide the best current models of Parkinson's disease. They could even play roles in normal age-related alterations in these systems. In this year, workers in this Branch continued to describe the poperties of knockout mice with deletions of the VMAT2 gene and other plasma membrane monaamine transporters. Aging studies documented clear reductions in locomotion, in amphetamine responsiveness and exaggerated age-related losses of dopaminergic markers in the heterozygous VMAT2 knockouts. Mice with deletions of VMAT2 and the plasma membrane transporters for DAT and SERT are viable and fertile and may display altered amphetamine responses. VMAT2 knockout mice continue to substantially enhance our understanding of mechanisms of age- related alterations in dopaminergic systems and actions of psychostimulants and locomotor systems. Studies completed suring this year also defined the two common haplotypes in the human VMAT2 gene, the patterns of imprinting through which they are inherited in humans, and in vitro expression patterns that provided more than 20-25% differences in cell lines expressing luciferase fusion constructions made with the two alternative human VMAT2 promoter regions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000161-08
Application #
6827531
Study Section
(MNRB)
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2003
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Hudson, Angela L; Nyamathi, Adeline; Bhattacharya, Debika et al. (2011) Impact of prison status on HIV-related risk behaviors. AIDS Behav 15:340-6
Fukushima, Setsu; Shen, Haowei; Hata, Harumi et al. (2007) Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193:55-62
Yamamoto, Hideko; Kamegaya, Etsuko; Hagino, Yoko et al. (2007) Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 51:237-44
Ghose, Subroto; Fujita, Masahiro; Morrison, Paul et al. (2005) Specific in vitro binding of (S,S)-[3H]MeNER to norepinephrine transporters. Synapse 56:100-4
Lin, Zhicheng; Walther, Donna; Yu, Xiao-Ying et al. (2005) SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet 14:1393-404
Dohi, Toshihiro; Kitayama, Shigeo; Morioka, Norimitsu et al. (2004) Regulation of dopamine and MPP+ transport by catecholamine transporters. Nihon Shinkei Seishin Yakurigaku Zasshi 24:43-7
Hall, F Scott; Sora, I; Uhl, G R (2003) Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28:620-8